Drew purchase gives significant boost to Escalon's fiscal 2005 revenues
This article was originally published in Clinica
Escalon Medical's hard-won acquisition of Drew Scientific last summer has paid off, as the former attributed the 83% increase in full-year revenues to the group's newest member.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.